Shanda Asset Management Holdings’s Tvardi Therapeutics TVRD Stock Holding History

Shanda Asset Management Holdings’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-770	Closed	-$474K	–	105
2020 Q2	$474K	Buy	+770	New	+$425K	0.04%	79
2019 Q3	–	Sell	-1,527	Closed	-$1.18M	–	42
2019 Q2	$1.18M	Hold	1,527	–	–	0.22%	18
2019 Q1	$1.08M	Hold	1,527	–	–	0.17%	32
2018 Q4	$715K	Hold	1,527	–	–	0.13%	36
2018 Q3	$1.32M	Hold	1,527	–	–	0.21%	21
2018 Q2	$1.05M	Hold	1,527	–	–	0.16%	30
2018 Q1	$681K	Hold	1,527	–	–	0.11%	32
2017 Q4	$673K	Buy	+1,527	New	+$696K	0.1%	36

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Shanda Asset Management Holdings's TVRD Position: Q3 2020 in Review

Shanda Asset Management Holdings sold out of Tvardi Therapeutics (TVRD) in Q3 2020, closing a stake of 770 shares — an estimated $474K sold.

Shanda Asset Management Holdings first reported a position in TVRD in Q4 2017 and held it in 8 quarters. The position peaked at $1.32M in Q3 2018. 161 funds tracked by Wall St. Rank hold TVRD as of Q3 2020.

Shanda Asset Management Holdings reported no remaining Tvardi Therapeutics position as of Q3 2020 after selling out during the quarter.
Shanda Asset Management Holdings sold 770 Tvardi Therapeutics shares in Q3 2020, an estimated $474K.
Shanda Asset Management Holdings first reported a position in Tvardi Therapeutics in Q4 2017 and held it in 8 quarters.
Shanda Asset Management Holdings's Tvardi Therapeutics position peaked at $1.32M in Q3 2018.
161 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2020.

Based on Shanda Asset Management Holdings's 13F filing for Q3 2020, filed 16 Nov 2020.